(TheNewswire)
Winnipeg – TheNewswire- April 16, 2024. Cytophage Technologies Ltd. ( TSXV:CYTO ) (“ Cytophage ” or the“Company”) is pleased to announce that Michael D. Cochrane, amanaging partner at Dixford Capital, LLC, has joined the Cytophageboard of directors as its newest member. He will also join the Auditand Finance Committee of the board. Michael’s extensive experienceas an investment banking veteran complements the board’s wealth ofexpertise in research, product development, commercialization, financeand corporate governance.
Chairman of the Cytophage board, Harold Wolkin, commented:” We arefortunate to attract a director of Michael’s calibre to our board soearly on after going public in February. Adding his expertise to ourteam contributes to our efforts to build an independent oversight bodyas Cytophage grows and evolves. His expertise infinance and the US capital markets will be of great value as the Companymoves forward. On behalf of the Cytophage board, I warmly welcomeMichael and look forward to working together.”
About Michael D. Cochrane
Michael D. Cochrane is an investment banking veteran with more than30 years of M&A and finance experience in both New York andToronto. During his 20-year career in New York, he held coverage andmanagement positions at Goldman, Sachs, Lehman Brothers, Credit Suisseand CIBC World Markets. Michael has specialized in M&A for growthcompanies focused on industry disruption through unique technologies,innovative business models or consolidation strategies.
Michael is currently the Managing Partner of Dixford Capital, anadvisory and investment company which focuses on growing small andmid-sized business through implementing operational, financing andcapital allocation strategies. Dixford is presently an investor inLakeview Mortgage Funding, The Milbrook Corporation, MCC Leasing,Aeris Communications and MacCosham Inc.
Previous positions include Managing Director in New York withUBS’s Global Industrial Group, Managing Director with CIBC WorldMarkets in Toronto and Co-Head of CIBC’s Global DiversifiedIndustries investment banking group. Between 2014 and 2019, Michaeltaught M&A and Economics courses in the MBA programs at Queen’sUniversity’s Smith School of Business and York University’sSchulich School of Business.
With respect to this recent appointment, Michael said: “I amexcited to work with the Cytophage directors and executives as theyexpand their commercialization efforts and growtheir capital markets presence in Canada and theUS. ”
For further information pleasecontact:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies ( TSXV:CYTO ) is apioneering biotechnology company dedicated to bacteriophage research,product development and commercialization. Committed to addressing theglobal challenge of antibiotic resistance, Cytophage advancesinnovative products that harness the power of bacteriophages to combatbacterial infections affecting human health, animal health, and foodsecurity.
Cautionary Statement onForward-Looking Information
This news release contains “forward-lookinginformation” and “forward-looking statements” (collectively,“forward-looking statements”) within the meaning of the applicableCanadian securities legislation. All statements, other than statementsof historical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are
described under the caption “Risk Factors” inCytophage’s Filing Statement dated January 30, 2024, which isavailable for view on SEDAR+ at www.sedarplus.ca. These risks includebut are not limited to, the risks associated with the bacteriophageindustry, such as operational risks in development or capitalexpenditures, the uncertainty of extensive regulatory approvalrequirements, government regulations, protection of intellectualproperty, product liability and rapid technological advancements.Forward-looking statements contained herein are made as of the date ofthis press release, and Cytophage disclaims, other than as required bylaw, any obligation to update any forward-looking statements whetheras a result of new information, results, future events, circumstances,or if management’s estimates or opinions should change, orotherwise. There can be no assurance that forward-looking statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements.
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2024 TheNewswire - All rights reserved.